- Home
- CMCL vs CRVS Comparison
CMCL vs CRVS Comparison
Compare CMCL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | CRVS |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.3M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CMCL | CRVS |
|---|---|---|
| Price | $29.21 | $6.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $13.75 |
| AVG Volume (30 Days) | 213.8K | ★ 1.7M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 908.66 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $228,245,000.00 | N/A |
| Revenue This Year | $55.55 | N/A |
| Revenue Next Year | $7.57 | N/A |
| P/E Ratio | $11.13 | ★ N/A |
| Revenue Growth | ★ 38.04 | N/A |
| 52 Week Low | $8.81 | $2.54 |
| 52 Week High | $38.75 | $9.60 |
Technical Indicators
Market Signals| Indicator | CMCL | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 35.98 |
| Support Level | $25.68 | $6.43 |
| Resistance Level | $27.41 | $7.18 |
| Average True Range (ATR) | 1.36 | 0.47 |
| MACD | 0.47 | -0.10 |
| Stochastic Oscillator | 98.29 | 17.20 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).